ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2523

Contemporary Prescription Opioid Use and Predictors Among Patients with Systemic Lupus Erythematosus

April Jorge1, Na Lu 2 and Hyon K. Choi 1, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hosptial, Boston, MA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: opioids and presciption trends, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: SLE – Clinical Poster III: Treatment

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: SLE is a complex illness that can be associated with chronic pain. In recent years, an international opioid epidemic has become a major public health concern and is attributed, in part, to prescription opioids. We assessed contemporary patterns of opioid prescribing among patients with SLE in a general population context and examined potential associations with prescription opioid use.

Methods: Using a United Kingdom general population database, we conducted a cohort study of adult SLE patients, identified by Read codes. The exposures of interest were opioid prescriptions between January 1, 2007 and December 31, 2016. We classified opioids as weak, including tramadol and codeine, and strong, including hydrocodone, morphine, fentanyl, oxycodone, hydromorphone, and methadone. We examined the proportion of patients receiving prescriptions for weak and strong opioids and performed logistic regression to assess whether prescription use of these medications varied by age, sex, duration of SLE, other medication use for SLE, comorbid conditions, lifestyle exposures, and socioeconomic status. We adjusted for age and sex.

Results: Of 10,784 SLE patients, (86% female, mean age 51.2 years), 32% were prescribed weak opioids and 10% were prescribed strong opioids during the study period. 21% and 7% received multiple prescriptions for weak and strong opioids, respectively. Concomitant diagnoses of fibromyalgia and OA each increased the odds of receiving prescription opioids (adjusted odds ratios [aOR] for strong opioids: 2.37 [96% CI 1.84-3.06] and 1.22 [95% CI 1.03-1.44] for fibromyalgia and OA, respectively) ( Table 1). SLE patients who were also taking NSAIDs, DMARDs, or glucocorticoids each had increased odds of receiving prescription opioids. Current smokers were also more likely to be prescribed prescription opioids. There was a trend towards higher odds of prescription opioid use with increasing deprivation score, a measure of socioeconomic status; the aOR was 1.33 (95% CI 1.03-1.71) for weak opioid use among the highest deprivation quintile.

Conclusion: In this general population-based cohort study, nearly one-third of SLE patients were prescribed weak opioids and 10% were prescribed strong opioids. Prescription opioid use is higher among patients who are also taking NSAIDs, glucocorticoids, and DMARDs, among those with lower socioeconomic status, and in those with concomitant fibromyalgia or OA. These findings indicate the use of these potentially dangerous medications among a substantial portion of SLE patients. Future studies should assess the impact of opioid usage on mortality and other important outcomes among patients with SLE.


Final Table 1 ACR abstract opioids in SLE


Disclosure: A. Jorge, None; N. Lu, None; H. Choi, AstraZeneca, 2, GSK, 5, Horizon, 5, Selecta, 5, Takeda, 5.

To cite this abstract in AMA style:

Jorge A, Lu N, Choi H. Contemporary Prescription Opioid Use and Predictors Among Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/contemporary-prescription-opioid-use-and-predictors-among-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/contemporary-prescription-opioid-use-and-predictors-among-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology